Symbiosis and Chemical Diversity Generation
共生和化学多样性的产生
基本信息
- 批准号:10552461
- 负责人:
- 金额:$ 53.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-01 至 2028-01-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAnabolismAnimalsAreaBacteriaBasic ScienceBiochemicalBiochemical PathwayBiologicalCell TherapyCellsChemicalsDevelopmentFDA approvedFamilyFundingGene LibraryGenerationsIndividualLaboratoriesLeadLearningLifeMethodsNatural ProductsNatural SourceNatureOceansOrganismParentsPathway interactionsPharmacologic SubstancePlanet EarthResearchSeaSideStructureSymbiosisTechnologyTestingTherapeuticTouch sensationVariantapplied biomedical researchbioactive natural productscompetitive environmentdesigndrug developmentdrug discoveryenzyme pathwayimprovedinnovationmarinemarine natural productnovelprogramsscaffoldsmall moleculesymbiontsynergismsynthetic biologytool
项目摘要
Project Summary/Abstract
Our overall research program aims to understand how chemical diversity arises in living organisms, and to
apply that diversity to important biomedical problems. This MIRA project focuses on two related scientific
areas: 1) a hypothesis-based approach to discovering new biosynthetic pathways and biomedically important
compounds from marine animals; and 2) understanding diversity-generating biosynthesis and applying it to
synthetic biology. The program synergizes with our applied biomedical research in drug discovery and
development, which is funded elsewhere. Because so much remains to be learned about how nature produces
diverse chemical scaffolds, our MIRA program is the key to providing innovative new materials and methods
that underlie the biomedical applications. We address two overarching problems:
1) There is a greater variety of animal life in the sea than anywhere else, including millions of diverse animal
species. Many marine animals live in highly competitive environments, and therefore they or their symbiotic
bacteria synthesize small molecule chemical defenses, which have found value as FDA-approved therapeutics
and lead compounds. They contain chemical scaffolds found only in the oceans and nowhere else on Earth.
Although many important marine animal natural products have been discovered, the biological and chemical
diversity of the oceans has barely been touched. Most marine animals are simply too small, rare, or variable to
provide a sufficient supply of compounds for drug discovery and development. In research that will continue
through this program, we eliminate the barriers to discovering new potential pharmaceuticals, enzymes, and
biochemical pathways from animals. We take a hypothesis-driven approach to determine who makes marine
natural products (animal, symbiont, or other) and how the compounds are made biochemically. This activity
leads directly to the discovery and development of novel chemicals and potential pharmaceuticals in the
applied (non-MIRA) side of our laboratory.
2) Instead of containing a single bioactive natural product, species of animals contain families of compounds,
where individual animals harbor variants of a parent structure. Sometimes, thousands of variants arise from a
single biochemical scaffold. Underlying this chemical diversity, we have shown that several biosynthetic
pathways are diversity generating, capable of synthesizing millions of derivatives. This unusual plasticity has
been applied as a tool for synthetic biology. Among other applications, one of the most exciting is the ability to
design compounds and then produce them in different kinds of living cells. For example, genetic libraries
encoding millions of unnatural natural products have already been created, and we are developing cell-based
therapies. Here, using hypothesis testing, we ask how diversity-generating pathways function: what makes a
pathway plastic, and how can these features be used in rational synthetic biology approaches. We apply the
resulting discoveries to biomedical problems in the non-MIRA, applied biomedical side of our laboratory.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eric W Schmidt其他文献
Eric W Schmidt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eric W Schmidt', 18)}}的其他基金
Modulating single cell types in the sensory nervous system
调节感觉神经系统中的单细胞类型
- 批准号:
10522412 - 财政年份:2022
- 资助金额:
$ 53.96万 - 项目类别:
Microbial Ecology-Guided Discovery of Antibacterial Drugs
微生物生态学引导抗菌药物的发现
- 批准号:
10446908 - 财政年份:2022
- 资助金额:
$ 53.96万 - 项目类别:
Modulating single cell types in the sensory nervous system
调节感觉神经系统中的单细胞类型
- 批准号:
10641952 - 财政年份:2022
- 资助金额:
$ 53.96万 - 项目类别:
Microbial Ecology-Guided Discovery of Antibacterial Drugs
微生物生态学引导抗菌药物的发现
- 批准号:
10565917 - 财政年份:2022
- 资助金额:
$ 53.96万 - 项目类别:
Marine symbiotic interactions for discovery of bioactive compounds
海洋共生相互作用发现生物活性化合物
- 批准号:
8906200 - 财政年份:2014
- 资助金额:
$ 53.96万 - 项目类别:
Marine symbiotic interactions for discovery of bioactive compounds
海洋共生相互作用发现生物活性化合物
- 批准号:
8562698 - 财政年份:2013
- 资助金额:
$ 53.96万 - 项目类别:
Directed posttranslational modifications for drug design and discovery
用于药物设计和发现的定向翻译后修饰
- 批准号:
8821631 - 财政年份:2013
- 资助金额:
$ 53.96万 - 项目类别:
Marine symbiotic interactions for discovery of bioactive compounds
海洋共生相互作用发现生物活性化合物
- 批准号:
9063428 - 财政年份:2013
- 资助金额:
$ 53.96万 - 项目类别:
相似海外基金
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中骨-脂肪相互作用
- 批准号:
10590611 - 财政年份:2022
- 资助金额:
$ 53.96万 - 项目类别:
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中的骨-脂肪相互作用
- 批准号:
10706006 - 财政年份:2022
- 资助金额:
$ 53.96万 - 项目类别:
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中骨-脂肪相互作用
- 批准号:
10368975 - 财政年份:2021
- 资助金额:
$ 53.96万 - 项目类别:
BCCMA: Foundational Research to Act Upon and Resist Conditions Unfavorable to Bone (FRACTURE CURB): Combined long-acting PTH and calcimimetics actions on skeletal anabolism
BCCMA:针对和抵抗不利于骨骼的条件的基础研究(遏制骨折):长效 PTH 和拟钙剂联合作用对骨骼合成代谢的作用
- 批准号:
10365254 - 财政年份:2021
- 资助金额:
$ 53.96万 - 项目类别:
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中骨-脂肪相互作用
- 批准号:
10202896 - 财政年份:2021
- 资助金额:
$ 53.96万 - 项目类别:
BCCMA: Foundational Research to Act Upon and Resist Conditions Unfavorable to Bone (FRACTURE CURB): Combined long-acting PTH and calcimimetics actions on skeletal anabolism
BCCMA:针对和抵抗不利于骨骼的条件的基础研究(遏制骨折):长效 PTH 和拟钙剂联合作用对骨骼合成代谢的作用
- 批准号:
10531570 - 财政年份:2021
- 资助金额:
$ 53.96万 - 项目类别:
Dissecting molecular mechanisms implicated in age- and osteoarthritis-related decline in anabolism in articular cartilage
剖析与年龄和骨关节炎相关的关节软骨合成代谢下降有关的分子机制
- 批准号:
10541847 - 财政年份:2019
- 资助金额:
$ 53.96万 - 项目类别:
Dissecting molecular mechanisms implicated in age- and osteoarthritis-related decline in anabolism in articular cartilage
剖析与年龄和骨关节炎相关的关节软骨合成代谢下降有关的分子机制
- 批准号:
10319573 - 财政年份:2019
- 资助金额:
$ 53.96万 - 项目类别:
Dissecting molecular mechanisms implicated in age- and osteoarthritis-related decline in anabolism in articular cartilage
剖析与年龄和骨关节炎相关的关节软骨合成代谢下降有关的分子机制
- 批准号:
10062790 - 财政年份:2019
- 资助金额:
$ 53.96万 - 项目类别:
Promotion of NAD+ anabolism to promote lifespan
促进NAD合成代谢以延长寿命
- 批准号:
DE170100628 - 财政年份:2017
- 资助金额:
$ 53.96万 - 项目类别:
Discovery Early Career Researcher Award